Clinical trials: Sitagliptin, completed
Diabetes Mellitus, Type 2
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient…
- Trial name
- COMETA (NCT03267576)
- Testing
- Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin
- Where
- 5 sites in Mexico
- Volunteers
- 64 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
Effects of Different Early Intensive Therapies on Long-term β-cell Function
The purpose of this study is to investigate and evaluate the effects of different oral antihyperglycaemic agents combined with short-term continuous subcutaneous insulin infusion(CSII)(1.CSII alone; 2.metformin and pioglitazone…
- Trial name
- NCT01471808
- Testing
- CSII, CSII, Metformin, Pioglitazone, CSII, Sitagliptin
- Volunteers
- 264 people
- Sponsor
- Sun Yat-sen University
Type 2 Diabetes Mellitus
30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
A 30-week extension to a 24-week study assessing the hemoglobin A1c (HbA1c)- and fasting plasma glucose (FPG)-lowering efficacy of the combination of sitagliptin and pioglitazone in patients with type 2 diabetes mellitus (T2DM)…
- Trial name
- NCT01028391
- Testing
- Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d., Metformin
- Volunteers
- 317 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Sitagliptin in the Elderly
Diabetes is common in the elderly; by the age of 70, approximately 25% of the population will have diabetes. Unfortunately, currently available medications are often not as effective or not well tolerated in older adults.
- Trial name
- NCT00451113
- Testing
- Sitagliptin 100 mg
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of British Columbia
Quality of Life, Type 2 Diabetes
Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients
Scarcity of local patients' quality of life data assessing diabetes treatment led us design a protocol to assess improvement in the quality of life of patients with Type II Diabetes mellitus.
- Conditions
- Quality of Life, Type 2 Diabetes, Metformin+Sitagliptin
- Trial name
- DQOL (NCT05167513)
- Testing
- Metformin / Sitagliptin Oral Tablet
- Where
- Pakistan
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Metabolic Syndrome, Hypertension
Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome
This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome.
- Trial name
- NCT00666848
- Testing
- Enalapril 5mg, Enalapril 10mg, Sitagliptin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University
Healthy
Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers
The objective was to investigate whether there was a drug-drug interaction between BI 10773 and sitagliptin when co-administered as multiple oral doses.
- Trial name
- NCT02172196
- Testing
- BI 10773, Sitagliptin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin.
- Trial name
- NCT01999218
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Glimerpiride
- Volunteers
- 1,326 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
ALPHA Sitagliptin Add on to Metformin (0431-103)
Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin
- Trial name
- NCT00833027
- Testing
- sitagliptin phosphate
- Volunteers
- 608 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperglycemia
Sitagliptin in Non-Diabetic Patients Undergoing General Surgery
The purpose of this study is to compare sitagliptin with a placebo for the prevention of high glucose after general surgery.
- Trial name
- NCT02741687
- Testing
- Sitagliptin, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart)
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Emory University
Healthy Subjects
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.
- Trial name
- NCT05236998
- Testing
- SID1903 (FDC), Dapagliflozin and Sitagliptin
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes
The purpose of this study is to see if the use of metformin and sitagliptin used in conjunction with insulin can improve the blood sugars of teenagers with Type 1 diabetes.
- Trial name
- NCT01718093
- Testing
- Sitagliptin, Metformin, Sitagliptin + Metformin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
Healthy
Drug Transporter Interaction Study PHENTRA_2015_KPUK
The objective of the present study is to contribute to establishing in vivo phenotyping procedures for organic anionic transporter polypeptide 1B1 (OATP1B1), organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic…
- Trial name
- NCT02743260
- Testing
- pitavastatin, Metformin, digoxin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Diabetes Mellitus Type 2
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
This 4 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin.
- Trial name
- NCT00754988
- Testing
- Metformin, Sitagliptin, Taspoglutide
- Where
- 148 sites in United States, Argentina and 21 more
- Volunteers
- 666 people
- Sponsor
- Hoffmann-La Roche
Healthy Subjects
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.
- Trial name
- NCT05453786
- Testing
- SID1903, SID1903-R1/SID1903-R2
- Where
- South Korea
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Type 2 Diabetes
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)
A three part study to demonstrate the bioequivalence of a single dose of the Final Market Image (FMI) of sitagliptin/metformin 50/500, 50/850 and 50/1000 mg Fixed-Dose Combination (FDC) tablet and co-administration of…
- Trial name
- NCT00961480
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500mg, Comparator: sitagliptin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden
This trial is conducted in Europe. The aim of this study is to investigate a retrospective database assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide from primary care centers in Sweden.
- Trial name
- NCT02077946
- Testing
- liraglutide, sitagliptin
- Where
- Sweden
- Volunteers
- 1,059 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
This is a study to assess the safety and efficacy of the addition of ipragliflozin once daily in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise…
- Trial name
- NCT02577003
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Diabetes Type 2
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme…
- Trial name
- NCT01413542
- Testing
- Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University